SynAct Pharma

SynAct Pharma Focuses on Developing Agonists Targeting the Melanocortin System. The melanocortin system is activated under inflammatory conditions and has anti-inflammatory effects, playing a crucial role in stimulating the healing process and restoring normal tissue function.SynAct Pharma's lead candidate drug, AP1189, is a first-in-class compound that targets the melanocortin system with once-daily oral dosing, stimulating relevant receptors of the melanocortin system while avoiding unwanted side effects. AP1189 has the potential to become a "pioneer" in resolution therapy—a new approach to treating inflammatory and autoimmune diseases by stimulating the immune system's healing mechanisms, unlike most current drugs that suppress the body's immune response.SynAct Pharma is currently testing its lead compound AP1189 in Phase II clinical trials for rheumatoid arthritis (RA) and plans to submit a clinical trial application in the first quarter of 2020 for a Phase II study in nephrotic syndrome (NS). With two Phase II clinical protocols established, SynAct will significantly increase the likelihood of success while enhancing the commercial value of AP1189.